PERPHENAZINE

Post-LOE

perphenazine

Pfizer

ANDAORALTABLET

Approved

Dec 1998

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

PERPHENAZINE (perphenazine) by Pfizer is actions perphenazine has actions at all levels of the central nervous system, particularly the hypothalamus. Approved for schizophrenia. First approved in 1998.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

ACTIONS Perphenazine has actions at all levels of the central nervous system, particularly the hypothalamus. However, the site and mechanism of action of therapeutic effect are not known.

Pharmacologic Class:

Phenothiazine

Indications (1)

schizophrenia

Clinical Trials (1)

NCT00480246Phase 1Completed

A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer

Started May 2007

Healthy

Company

Worked on PERPHENAZINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.